

occurring using intensive surveillance techniques and prevention schemes. These tools also are making genetic testing decisions and management of hereditary cancer syndromes even more complicated, underscoring the necessity for dedicated cancer genetic counselors and cancer risk assessment clinics that can best use these evolving tools to provide appropriate and evidence-based health care consultation.

Financial Disclosures: None reported.

REFERENCES

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. *CA Cancer J Clin*. 2006; 56:106-130.
2. Macdonald JS. Adjuvant therapy of colon cancer. *CA Cancer J Clin*. 1999;49: 202-219.
3. Levin B, Barthel JS, Burt RW, et al. Colorectal Cancer Screening Clinical Practice Guidelines. *J Natl Compr Canc Netw*. 2006;4:384-420.
4. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. *N Engl J Med*. 2003; 348:919-932.
5. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). *Dis Colon Rectum*. 1991;34:424-425.
6. Kievit W, de Bruin JH, Adang EM, et al. Current clinical selection strategies for identification of hereditary non-polyposis colorectal cancer families are inadequate: a meta-analysis. *Clin Genet*. 2004;65:308-316.
7. Gruber SB. New developments in Lynch syndrome (hereditary nonpolyposis colorectal cancer) and mismatch repair gene testing. *Gastroenterology*. 2006;130: 577-587.
8. Lynch HT, Smyrk TC, Watson P, et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. *Gastroenterology*. 1993;104:1535-1549.
9. Sankila R, Aaltonen LA, Jarvinen HJ, Mecklin JP. Better survival rates in patients with MLH1-associated hereditary colorectal cancer. *Gastroenterology*. 1996; 110:682-687.
10. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. *J Natl Cancer Inst*. 1997;89:1758-1762.
11. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst*. 2004;96:261-268.
12. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res*. 1998;58:5248-5257.
13. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). *N Engl J Med*. 2005;352:1851-1860.
14. Piñol V, Castells A, Andreu M, et al; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. *JAMA*. 2005;293:1986-1994.
15. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. *Proc Natl Acad Sci U S A*. 1998;95:6870-6875.
16. Balmaña J, Stockwell DH, Steyerberg EW, et al. Prediction of *MLH1* and *MSH2* mutations in Lynch syndrome. *JAMA*. 2006;296:1469-1478.
17. Chen S, Wang W, Lee S, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. *JAMA*. 2006;296:1479-1487.
18. Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. *N Engl J Med*. 2006;354:2751-2763.
19. Wijnen J, van der Klift H, Vasen H, et al. *MSH2* genomic deletions are a frequent cause of HNPCC. *Nat Genet*. 1998;20:326-328.
20. Lynch HT, Shaw MW, Magnuson CW, Larsen AL, Krush AJ. Hereditary factors in cancer: study of two large midwestern kindreds. *Arch Intern Med*. 1966;117: 206-212.

Explaining, Predicting, and Treating HIV-Associated CD4 Cell Loss After 25 Years Still a Puzzle

W. Keith Henry, MD

Pablo Tebas, MD

H. Clifford Lane, MD

THE CLINICAL SYNDROME OF AIDS IS DUE TO INFECTION with the human immunodeficiency virus (HIV), which causes a progressive immunodeficiency characterized by the loss of CD4 T lymphocytes coupled with an immunosuppression related to global activation of the immune system. Since the seminal article by Mellors et al in 1996,¹ it has been known that as a group, individuals with a higher HIV RNA viral load tend to progress to AIDS and death at a more rapid rate than those with lower viral loads, and that different prognostic information can be derived from the CD4 cell count and the viral load. The conventional wisdom is that the CD4 cell count represents the current state of immune deficiency, whereas the viral load

reflects the rate at which the immune system will further deteriorate.²

The report by Rodríguez and colleagues³ in this issue of *JAMA* challenges the notion that, at the individual level, a limited number of HIV measurements over a short period of time provide meaningful prognostic information regarding the rate of CD4 cell decline and by extension the risk of opportunistic infections. Clinicians treating patients with HIV encounter some patients with low plasma viral levels who experience rapid progression. What mechanism is responsible for their profound and quick CD4 cell loss? On the other end of the spectrum are those patients with high-level HIV viremia who respond clinically like sooty mangabeys infected with simian immunodeficiency virus (SIV),⁴

Author Affiliations: HIV Program, Hennepin County Medical Center and the University of Minnesota, Minneapolis (Dr Henry); Division of Infectious Diseases, University of Pennsylvania, Philadelphia (Dr Tebas); and Division of Clinical Research and Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, Md (Dr Lane).

Corresponding Author: Keith Henry, MD, Hennepin County Medical Center, 701 Park Ave R7, Minneapolis, MN 55415 (keithh6680@aol.com).

See also p 1498.

which can tolerate high levels of SIV replication without disease progression. Are such patients statistical extremes in an otherwise simple and uncontested paradigm, or are clinicians and researchers missing something?

Rodríguez et al have taken the perspective of the individual patient in attempting to quantify how much of the variability of the individual CD4 cell loss is explained by the baseline plasma HIV RNA viral load.³ They used 3 clinical cohorts from several academic medical centers and confirmed their findings using the Multicenter AIDS Cohort Study (MACS) public data set, the same cohort that was used originally by Mellors et al.¹ Although the selection of patients who did not receive treatment immediately and the relatively short follow-up might have introduced some bias, the validation in a different well-characterized cohort is reassuring. The provocative main finding from their study was that the presenting plasma HIV RNA load predicted no more than 10% of the observed CD4 cell loss in patients with chronic untreated HIV infection.

What factor(s) explain the other 90%? Twenty-five years into the HIV epidemic, a complete understanding of what drives the decay of CD4 cells—the essential event of HIV disease—is still lacking. Direct and indirect effects of HIV infection, not fully measured by plasma HIV RNA levels, reverberate through a host's unique genetic and immunologic environment. HIV persists in tissues throughout the body and likely sets off chain reactions of acute and chronic immune disturbances.⁵ Some of the mechanisms involved in this process most likely have been identified, but it is uncertain whether these factors are independent of one another, driven directly by the virus (or indirectly by the state of chronic immune activation associated with HIV infection), or a combination of both. In many cases it is difficult to elucidate what is cause and what is effect in these observations.

The importance of the host's genetic background in HIV pathogenesis has been increasingly recognized and appreciated. For instance, it has been known that some HLA patterns are associated with slower disease progression⁶ and that individuals heterozygous for the $\Delta 32$ mutation in the CC chemokine receptor 5 (CCR5) tend to progress more slowly.⁷ Moreover, proteins like TRIM5 α make some primate species resistant to HIV disease,⁸ and polymorphisms in APOBEC3G⁹ may play a role in disease progression. Other recently reported likely important genetic factors potentially influencing HIV progression include *CCL3L1* gene duplications¹⁰ and polymorphisms in genes participating in postentry steps of the HIV-1 life cycle (*PML*, *TSG101*, and *PPIA*).¹¹

The acute phase of HIV infection may cause profound damage to the immune system that may not be clearly linked to ongoing levels of HIV viremia observed during the chronic phase. Events that occur during acute HIV infection in the resting memory CD4 cells in intestinal mucosa might herald risk for subsequent disease progression, yet the degree of massive tissue CD4 cell depletion is not reflected by the

level of peripheral CD4 cells.¹² Furthermore, residual disturbance of the lymph node architecture¹³ and the amount of functional thymic tissue persisting after aging and HIV-related damage also may influence CD4 cell restoration.¹⁴ Immune activation during the chronic phase of infection is also important and may be a better predictor of disease progression than HIV RNA viral load.¹⁵ Many previously disparate processes may ultimately be shown to significantly interact and affect CD4 function and homeostasis in the setting of HIV infection. For example, very recent reports describe the critical role that the up-regulation of the programmed cell death protein PD-1 in CD4 and CD8 T-cells might have in the pathogenesis of HIV disease,¹⁶ and how blockage of this protein can reverse immune dysfunction and improve control of viremia in vitro.¹⁷ The puzzle of HIV pathogenesis keeps getting more pieces added to it.

The findings presented by Rodríguez et al³ provide support to those who favor nonvirological mechanisms as the predominant cause of CD4 cell loss; however, these data should be interpreted with caution, and the issue of a single viral load as a prognostic marker should be separated from the role of viral replication in HIV pathogenesis. Measurements of a limited number of viral load levels may not provide a full picture regarding the overall impact of viral replication on the patient over the course of disease. To provide such a picture would require examination of a time-dose relationship for viral load and comparison with changes in CD4 T cells over an extended period of time. In addition, censoring patients who initiated antiretroviral therapy within 6 months of study may have eliminated a cohort of patients with the most rapid declines in CD4 cell counts from the analysis.

The study by Rodríguez et al may have several important clinical implications. The first and more straightforward is that baseline measurements of viral load alone should have less of a role in driving decisions on when to start antiretroviral therapy for an individual patient; these initial viral load levels cannot predict how rapidly the disease will progress. Current treatment guidelines^{18,19} in the developed world progressively have recognized the limited role that HIV-RNA level plays in this decision and have increasingly stressed the importance of the baseline CD4 cell count. Interestingly, guidelines in the developing world²⁰ have reached the same conclusions, but have been based more on economic arguments. The secondary importance of baseline plasma HIV RNA levels does not diminish its critical importance in monitoring viral load responses after the initiation of antiretroviral therapy to document complete viral suppression and prevent the development of resistance. However, the seemingly useful practice of combining a CD4 cell count and plasma HIV RNA levels to assess an individual patient's prognosis for AIDS progression²¹ or response to highly active antiretroviral therapy²² needs reexamination.

The second and potentially more exciting implication of the findings of Rodríguez et al is that future improvements in the treatment of HIV infection and AIDS may result from

improved understanding of the 90% of CD4 cell depletion that remains enigmatic. The current paradigm of HIV treatment is the continuous use of antiretroviral combinations (targeting the widespread effects of ongoing HIV replication) for long periods of time, which now could approximate a normal life span. This approach has led to the most dramatic change in the prognosis of any disease in the last 2 decades, from usually lethal to regularly manageable. However, the sustainability of the current paradigm for the more than 40 million HIV-infected individuals and the more than 4 million new HIV infections per year is at best questionable.²³

Unfortunately, treatment strategies that do not directly target HIV have not proven successful. Only 2 immunomodulators have been approved for the treatment of HIV-related disease: (1) interleukin 2, a cytokine used in some European countries to increase the CD4 cell count²⁴; and (2) thalidomide, a tumor necrosis factor α antagonist for aphthous ulcers associated with HIV infection.²⁵ This is a meager list when compared with the 24 currently approved antiretroviral drugs, all of which directly inhibit stages of HIV replication.

As in the treatment of cardiovascular disease, developing therapeutic strategies for HIV that target both the etiology and the end organ damage may be more effective than either alone. Therapies focused on some of the nonviral factors (discussed above) may start to address the bulk of the “iceberg” below the tip of the measureable plasma HIV level. A better understanding of the immunologic and genetic factors that drive HIV-associated CD4 cell loss may translate to novel therapeutic approaches that could favorably shift the pathogen-host balance. In that direction, the first drugs that target a cellular factor (the chemokine receptor CCR5) have reached the clinical arena and are currently in phase 3 trials.^{26,27} Discovering and developing therapies that target key nonviral factors has the potential over the decades ahead to build on the success of antiretroviral therapy and expand access to sustainable effective therapy.

Financial Disclosures: Dr Henry reports that he conducts research funded by the National Institutes of Health, the Centers for Disease Control and Prevention, Bristol-Myers Squibb, Serono, Thera, and Pfizer; is on the speakers bureau for GlaxoSmithKline, Bristol-Myers Squibb, Roche, and Gilead; has received honoraria from GlaxoSmithKline, Bristol-Myers Squibb, and Gilead; and has been a consultant for GlaxoSmithKline, Bristol-Myers Squibb, and Gilead. Dr Tebas reports that he receives grant support from the National Institutes of Health, Pfizer, Roche, VIRxSYS, Tibotec, Primagen, Gilead, VGX, and Wyeth; has received honoraria from Bristol-Myers Squibb and GlaxoSmithKline; and has been a consultant for Bristol-Myers Squibb and Primagen. Dr Lane reports that he has received research support from Novartis and is a co-inventor in a US government-held patent of interleukin 2 for use in HIV infection.

REFERENCES

©2006 American Medical Association. All rights reserved.

- Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. *Science*. 1996; 272:1167-1170.
- Coffin J. HIV and viral dynamics. Presented at: 11th International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia.
- Rodríguez B, Sethi AK, Cheruvu VK, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. *JAMA*. 2006;296:1498-1506.
- Rey-Cuille MA, Berthier JL, Bomsel-Demontoy MC, et al. Simian immunodeficiency virus replicates to high levels in sooty mangabeys without inducing disease. *J Virol*. 1998;72:3872-3886.
- Stebbing J, Gazzard B, Doueck DC. Mechanisms of disease: where does HIV live? *N Engl J Med*. 2004;350:1872-1880.
- Migueles SA, Sabbaghian MS, Shupert WL, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. *Proc Natl Acad Sci U S A*. 2000;97:2709-2714.
- Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CCR5 structural gene: Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. *Science*. 1996;273:1856-1862.
- Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5 α restricts HIV-1 infection in Old World monkeys. *Nature*. 2004;427:848-853.
- An P, Bleiber G, Duggal P, et al. APOBEC3G genetic variants and their influence on the progression to AIDS. *J Virol*. 2004;78:11070-11076.
- Gonzalez E, Kulkarni H, Bolivar H, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. *Science*. 2005;307:1434-1440.
- Bleiber G, May M, Martinez R, et al. Use of a combined ex vivo/in vivo population approach for screening of human genes involved in the human immunodeficiency virus type 1 life cycle for variants influencing disease progression. *J Virol*. 2005;79:12674-12680.
- Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. *J Exp Med*. 2004;200:749-759.
- Schacker TW, Nguyen PL, Beilman GJ, et al. Collagen desposition in HIV-1 infected lymphatic tissues and T cell homeostasis. *J Clin Invest*. 2002;110:1133-1139.
- Delgado J, Leal M, Ruiz-Mateos E, et al. Evidence of thymic function in heavily antiretroviral treated human immunodeficiency virus type 1-infected adults with long-term virologic treatment failure. *J Infect Dis*. 2002;186:410-414.
- Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. *J Infect Dis*. 1999;179:859-870.
- Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction [published online ahead of print August 20, 2006]. *Nat Med*. doi:10.1038/nm1482.
- Day CL, Kaufman DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression [published online ahead of print August 20, 2006]. *Nature*. doi:10.1038/nature05115.
- DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. May 4, 2006. <http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>. Accessed August 29, 2006.
- Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA Panel. *JAMA*. 2006; 296:827-843.
- World Health Organization-HIV/AIDS Programme. Antiretroviral therapy for HIV infection in adults and adolescents in resource limited settings: towards universal access: recommendations for a public health approach: 2006 revision. <http://www.who.int/hiv/pub/guidelines/WHO%20Adult%20ART%20Guidelines.pdf>. Accessed August 29, 2006.
- Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers in HIV infection. *Ann Intern Med*. 1997;126:946-954.
- Egger M, May M, Chene G, et al. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. *Lancet*. 2002;360:119-129.
- UNAIDS. 2006 Report on the global AIDS epidemic. http://www.unaids.org/en/HIV_data/2006GlobalReport/default.asp. Accessed August 30, 2006.
- Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. *N Engl J Med*. 1996; 335:1350-1356.
- Jacobson JM, Greenspan JS, Spritzler J, et al; National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. *N Engl J Med*. 1997;336:1487-1493.
- Deeks SG. Challenges of developing R5 inhibitors in antiretroviral naïve HIV-infected patients. *Lancet*. 2006;367:711-713.
- Lederman MM, Penn-Nicholson A, Cho M, Mosier D. Biology of CCR5 and its role in HIV infection and treatment. *JAMA*. 2006;296:815-826.

(Reprinted) JAMA, September 27, 2006—Vol 296, No. 12 1525